Oedema disease, which had largely disappeared in many countries, is seen to be increasing and again affecting pig herds across the whole of Europe. Veterinary surgeons are unsure of the reasons for this resurgence.
The vaccine, Ecoporc Shiga, launched in response to this situation, was developed by IDT Biologika.
“Most farms start vaccination when mortality due to oedema disease exceeds three per cent. While mortality on some farms can top 15 per cent, the average on vaccinating farms is probably 6.7 per cent,” said IDT veterinarian, Dr Rike Schmelz.
Piglets are injected intra-muscularly from four days old with a single 1ml dose. It induces a high level of immunity against shigatoxin, produced by the E coli bacteria that cause oedema disease.
The vaccine is judged to have saved the lives of three million pigs, with an estimated value of over 100 million Euros, at an average of 20-22 kg liveweight. This takes no account of the poor performance suffered by those pigs that survive and tend to remain runt-like.
Vaccination proved highly successful on German farms where the disease was found to reduce the margin per sow by as much as 83 Euros, equivalent to 41,000 Euros for a 500-sow herd. Currently used across much of the EU, the vaccine is protecting over ten per cent of pigs in some countries.
Shigatoxin is one of the most potent naturally-occurring toxins. It destroys fine blood vessels causing fluid to accumulate in the tissue. By acting as a preventive, vaccination can significantly reduce the use of antibiotics.
August 7, 2018 - IDT Biologika